CORT Stock — Corcept Therapeutics Incorporated: Cash, EV, Pipeline

What they do

We are a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. Cortisol plays a significant role in the body’s response to stress and is essential for survival.

Source: 10-K FY2025 via SEC EDGAR

Share price

$72.77

Market cap

$7,964.2M

Cash

$662.3M

Enterprise value

$7,301.9M

Balance sheet

Cash	$662.3M
Debt	$0.0M
Net cash	$662.3M
Enterprise value	$7,301.9M
Basic shares	109.4M shares
Fully diluted shares	133.7M shares
Fully diluted market cap	$9,732.1M
Cash per share	$6.05
Quarterly burn	+$33.5M generated

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common

108.1M

Pre-funded warrants

0.0M

Options

24.0M

RSUs

1.7M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

—

FDSO

133.7M

Cap table as of 2026-07-22.

Price history

Loading CORT daily closes…

Loading price history…

Next catalyst

Miricorilant (Cohort A) · Now - Nov 24, 2026 Now · Phase 2 · Nonalcoholic Steatohepatitis (NASH); Metabolic Dysfunction-associated Steatohepatitis (MASH)

Recently reported

Relacorilant Phase 2 Positive · 2026-10-26

Primary: Median progression-free survival (PFS) by investigator and objective response rate (ORR) in Part A of the Phase 2 BELLA trial, a single-arm, open-label trial of Lifyorli in combination with nab-paclitaxel and bevacizumab in platinum-resistant ovarian cancer — Patients treated with Lifyorli plus nab-paclitaxel and bevacizumab demonstrated a median PFS by investigator of 7.2 months and an ORR in BELLA of 59%

· Median OS had not been reached at the time of the primary analysis; 88% of patients were alive at the 6-month OS timepoint

· In bevacizumab-naive patients, median PFS was 8.1 months and ORR was 66%, with an OS at the 6-month mark of 91%

· BELLA Part A enrolled 95 women with recurrent, platinum-resistant ovarian cancer at approximately 45 sites

· Historical comparison in the release: median PFS of 5.4 months for Lifyorli plus nab-paclitaxel and 3.9 months for nab-paclitaxel alone in the pivotal Phase 3 ROSELLA study; ORR 37% and 30%, respectively

Safety: Safety events were consistent with the known profiles of each individual agent in the combination, with no new safety signals identified; the most common (≥25% of patients) adverse events were neutropenia, anemia, nausea, asthenia, nail disorder, peripheral neuropathy, fatigue, and leukopenia

Source release →

Dazucorilant 300 mg Mixed · 2026-04-30

Source release →

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Now - Nov 24, 2026 Now	Miricorilant (Cohort A)	Phase 2	Nonalcoholic Steatohepatitis (NASH); Metabolic Dysfunction-associated Steatohepatitis (MASH)	—
Now - Nov 24, 2026 Now	Nenocorilant 200 mg	Phase 2	Neoplasms	—
Nov 12 - Dec 24 in 5d	Dazucorilant 300 mg	Phase 2	Amyotrophic Lateral Sclerosis	—
Dec 11, 2026 - Jan 22, 2027 in 5 wks	Miricorilant	Phase 1	Nonalcoholic Steatohepatitis (NASH); Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic; Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)	—
Jan 12 - Feb 23 in 9 wks	relacorilant	Phase 2	Cushing Syndrome	Q4 2026 Est. Nov 15, 2026 · quarter midpoint

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Korlym

Approved · Active Modality: small molecule

Aliases mifepristone

Target glucocorticoid receptor (GR)

Indications

Hypercortisolism (Cushing's syndrome) (Approved)

Status note Marketed in the U.S. since 2012 for hypercortisolism; authorized generic version launched June 2024.

Relacorilant

Approved · Active Modality: small molecule

Aliases Lifyorli

Target glucocorticoid receptor (GR)

Partnerships University of Chicago: randomized placebo-controlled Phase 2 of relacorilant + enzalutamide in prostate cancer (pre-prostatectomy), licensed patents. ARCAGY-GINECO: Phase 2 STELLA trial of relacorilant + nab-paclitaxel in 50 cervical cancer patients

Indications

Hypercortisolism (Phase 3)
Platinum-resistant ovarian cancer (with nab-paclitaxel) (Approved)
Pancreatic cancer (with nab-paclitaxel + gemcitabine) (Phase 2)
Cervical cancer (with nab-paclitaxel) (Phase 2)
Prostate cancer (with enzalutamide) (Phase 2)
Other solid tumors (Phase 2)

Catalysts

— fourth quarter of 2026

Status note Hypercortisolism: NDA submitted December 2024; FDA issued Complete Response Letter December 30, 2025. Approved as Lifyorli in March 2026 in combination with nab-paclitaxel for platinum-resistant ovarian cancer. Phase 2 trials: BELLA (ovarian, Part A enrollment completed December 2025), TRIDENT (pancreatic, initiated December 2025), STELLA (cervical, initiating Q1 2026).

Nenocorilant

Stage not disclosed · Active Modality: small molecule

Target glucocorticoid receptor (GR)

Indications

Cancer (with immunotherapy) (Stage not disclosed)

Status note Proprietary selective cortisol modulator; trial stage not stated in excerpts.

Miricorilant

Phase 2 · Active Modality: small molecule

Target glucocorticoid receptor (GR)

Indications

MASH (Phase 2)

Status note Selective cortisol modulator for MASH. Phase 1b completed; randomized double-blind placebo-controlled Phase 2 initiated October 2023.

Dazucorilant

Phase 2 · Active Modality: small molecule

Target glucocorticoid receptor (GR)

Indications

ALS (Phase 2)

Status note Selective cortisol modulator for ALS; FDA Fast Track Designation and orphan drug status. Phase 2 DAZALS (249 patients, 24 weeks) did not meet its primary endpoint. No discontinuation language in the excerpts.

Per-asset detail extracted from the 10-Q filed 2026-07-29. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Relacorilant 150 mg
Lead indication	Ovarian Neoplasm
Lead phase	Phase 3
Active trials	9
Collaborator trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05257408	Phase 3	Active, not recruiting	Sponsor	CORT	—	Ovarian Neoplasm; Fallopian Tube Neoplasms; Peritoneal Neoplasms	Q4 2026
NCT05407324	Phase 2	Recruiting	Sponsor	CORT	—	Amyotrophic Lateral Sclerosis	—
NCT03604198	Phase 2	Active, not recruiting	Sponsor	CORT	—	Cushing Syndrome	Q4 2026 Est. Nov 15, 2026 · quarter midpoint
NCT07259317	Phase 2	Recruiting	Sponsor	CORT	—	Adenocarcinoma; Carcinoma, Pancreatic Ductal	Q4 2026 Est. Nov 15, 2026 · quarter midpoint
NCT06906341	Phase 2	Recruiting	Sponsor	CORT	—	Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Neoplasms	Q4 2026 Est. Nov 15, 2026 · quarter midpoint
NCT06108219	Phase 2	Active, not recruiting	Sponsor	CORT	—	Nonalcoholic Steatohepatitis (NASH); Metabolic Dysfunction-associated Steatohepatitis (MASH)	—
NCT07276373	Phase 2	Recruiting	Sponsor	CORT	—	Neoplasms	—
NCT07553663	Phase 1	Recruiting	Sponsor	CORT	—	Nonalcoholic Steatohepatitis (NASH); Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic; Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)	—
NCT06947304	Phase 1	Active, not recruiting	Sponsor	CORT	—	Nonalcoholic Steatohepatitis (NASH); Metabolic Dysfunction-Associated Steatohepatitis (MASH); Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)	—
NCT06099769	Phase 2	Recruiting	Collaborator	Memorial Sloan Kettering Cancer Center	—	Metastatic Breast Cancer	—
NCT06689254	Phase 2	Recruiting	Collaborator	Christiaan Vinkers	—	Treatment-resistant PTSD	—

Sponsor-matched active trials from ClinicalTrials.gov (9 as sponsor, 2 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 11 active trials for Corcept Therapeutics on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Tang Capital Partners	1,500,000	no change	5.92%	2026-08-14
Perceptive Advisors	398,385	+348,385	0.54%	2026-08-14
Boxer Capital	335,500	+85,500	2.20%	2026-08-14
ADAR1 Capital Management	0	-8,000	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

CORT — Corcept Therapeutics Incorporated ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Recently reported

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

CORT — Corcept Therapeutics Incorporated